Related Experiment Video
Updated: May 12, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
[Historical milestones in the study of pulmonary hypertension]
A K Osokina1, O V Rodnenkov1, T V Martynyuk1,2
1Chazov National Medical Research Center of Cardiology.
Abstract:
The article describes the historical aspects of the discovery of the pulmonary circulation and the study of pulmonary hypertension (PH) as a pathophysiological condition with a key hemodynamic characteristic - an increase in pressure in the pulmonary artery. The complexity of PH treatment is due to the association with various cardiovascular and respiratory diseases, which requires a multifaceted holistic interdisciplinary approach with the active participation of the physician and the patient. Currently, the guide for successful clinical practice are clinical guidelines covering the full range of diagnostic and therapeutic measures for various groups of PH. The development of guidelines is the result of a long way of studying morphology, pathophysiology, creating and researching of pathogenetic medical drugs, clinical observation of patients in the framework of studies and registries.
More Related Videos
08:34Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
10:20Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...